September 19, 2023 12:09 PM EDT

MarketingRx roundup: Abbott teams with WeightWatchers for glucose monitoring; Haleon’s Advil starts ‘pain equity’ effort

Beth Snyder Bulik

Senior Editor

Abbott is partnering with WeightWatchers (WW) to help dieters with type 2 diabetes better track their glucose levels. WW members can now access the data …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

MarketingRx roundup: Abbott teams with WeightWatchers for glucose monitoring; Haleon’s Advil starts ‘pain equity’ effort

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Exclusive: Florida cancer biotech raises $100M Series A

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Mar­ket­ingRx roundup: Ab­bott teams with Weight­Watch­ers for glu­cose mon­i­tor­ing; Ha­le­on’s Advil starts ‘pain eq­ui­ty’ ef­fort

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

MarketingRx roundup: Abbott teams with WeightWatchers for glucose monitoring; Haleon’s Advil starts ‘pain equity’ effort

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Exclusive: Florida cancer biotech raises $100M Series A

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.